Logo Logo
Hilfe
Hilfe
Switch Language to English

Schworm, Benedikt; Luft, Nikolaus; Keidel, Leonie F.; Kreutzer, Thomas C.; Herold, Tina R.; Priglinger, Siegfried G. und Siedlecki, Jakob (2021): Vanishing pachy-choroid in pachychoroid neovasculopathy under long-term anti-vascular endothelial growth factor therapy. In: BMC Ophthalmology, Bd. 21, Nr. 1, 269

Volltext auf 'Open Access LMU' nicht verfügbar.

Abstract

BackgroundTo investigate the diagnostic value of choroidal thickness in the definition of pachychoroid neovasculopathy (PNV), especially in eyes treated with anti-vascular endothelial growth factor (VEGF) therapy.MethodsTwenty-two consecutive eyes of 11 patients with uni- or bilateral PNV were analyzed. Anti-VEGF treatment was correlated with changes in choroidal thickness on enhanced depth imaging optical coherence tomography.ResultsThere were 14 eyes with PNV and 8 non-neovascular partner eyes. Mean age was 64.24.0 (range: 60-72), total follow-up was 1.8 +/- 0.4 (1-2) years. In PNV eyes, choroidal thickness at baseline was 400 +/- 58 (269-485) mu m. After two years and 13 anti-VEGF injections on average, a mean reduction of -39 +/- 10 (-26 to -56) % to final 241 +/- 52 (162-327) mu m was observed (p <0.0001). Meanwhile, choroidal thickness in the partner eyes remained stable (p >0.13 for all comparisons). A significant correlation of choroidal thinning and anti-VEGF injection rate was observed at year one (r=-0.79;R-2 =0.63;p =0.00073) and two (r=-0.69;R-2 =0.48;p =0.019). While 85.7% of PNV eyes exceeded a pachychoroid threshold of >= 350 mu m at baseline, this figure dropped to 21.4% at year one and 0% at year two.Conclusion In PNV, choroidal thickness significantly decreases with anti-VEGF therapy, resembling a vanishing pachy-choroid, and thus does not represent a valid long-term diagnostic criterium, especially when differentiating PNV from nAMD.

Dokument bearbeiten Dokument bearbeiten